Načítá se...
Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...
Uloženo v:
| Vydáno v: | ACS Omega |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Chemical Society
2020
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758955/ https://ncbi.nlm.nih.gov/pubmed/33376898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c04942 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|